10 Years of Allele Biotech

Facts about Allele’s 10 years in business:

Products

New product lines added in 2009: iPS cells, Camelid Antibodies, DNA synthesis chemicals, Recombinant Proteins

Highlights: HiTiter Lentiviral Systems, Baculovirus for Mammalian Expression (BacMam), Feeder Cells, shRNA on Viral Vectors, shRNA Validation FP Vector, ProperFold Protein Folding Vector, Validated AllHPLC synthetic siRNA

New Service Groups in 2009: Viral Packaging, RNAi Validation/Screening, FP-based Assay Development

Numbers

Since April, we have added at least one new product every week! We currently run one new promotion per week as well.

A bit of history–did you know that…

Allele Biotech obtained 5 NIH grants in its first three years since establishment. As a matter of fact, Allele Biotech was funded entirely by NIH grants

Allele filed its first patent application in its second year of operation, which was on DNA-driven RNAi and resulted in an outlicensing deal with Promega. As result of the applications, Allele has received 3 US patents on DNA-encoded shRNA, siRNA using promoters such as U6 and H1.

During the past 10 years, Allele was the first to sell U6-based RNAi vectors, the only supplier of bFGF-expressing feeder cells for iPSC, most likely a top 3 provider of baculovirus expression systems, camelid antibody products, iPS creating viral particles, and the most active commercial developer of fluorescent proteins.

Our Message to Our Followers

What we at Allele Biotech see ourselves doing in the sense of fulfilling an obligation to the society and our peers in scientific research: Salvation and success through innovation and diligence, reaching for a place of efficient sustainability where monopolies do not win and ordinary people have the chance to realize their dreams.

We don’t believe in dominance by a few big boys, because we don’t believe that they can provide researchers with the best value. We want people that deal with us to see that there is room for development by an individual or a small group of highly dedicated and talented persons, as your own group in academia or a small company can do. This is the beauty of our industry and our field.

We like to see our people challenge existing doctrine and hypothesize new ones, after all, isn't that how we are trained through grad school and postdoc training, but somehow and somewhere it starts to seem to difficult to do, especially when you try to get a paper accepted or a grant rated among the top 10%. We don’t want to lose our edge, even if we have to learn to better place it. We will continue to move this way, and we want you to come along for the ride.